Canadian Implantable Defibrillator Study (CIDS)
From Ask Dr Wiki
Contents |
Background
A total of 659 patients with resuscitated VF or VT or with unmonitored syncope were randomly assigned to treatment with the ICD or with amiodarone. The primary outcome measure was all-cause mortality, and the secondary outcome was arrhythmic death.
Results
At 5 years, 85.4% of patients assigned to amiodarone were still receiving it at a mean dose of 255 mg/day, 28.1% of ICD patients were also receiving amiodarone, and 21.4% of amiodarone patients had received an ICD. A nonsignificant reduction in the risk of death was observed with the ICD, from 10.2% per year to 8.3% per year. A nonsignificant reduction in the risk of arrhythmic death was observed, from 4.5% per year to 3.0% per year.
Conclusions
A 20% relative risk reduction occurred in all-cause mortality and a 33% reduction occurred in arrhythmic mortality with ICD therapy compared with amiodarone which did not reach statistical significance.
Reference
Connolly S, Gent M, Roberts R, for the CIDS investigators. Canadian Implantable Defibrillator Study (CIDS). A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000,101:1297-1302.
